Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis

被引：0
|
作者：
Katsuyuki Nagatoya
Kazuhiko Nishimoto
Nobuhisa Shibahara
Toshikazu Takahashi
Hironori Kanehara
Nobuyuki Ueno
Hideaki Yasuda
Shigeki Okada
Haruhiko Ueda
Kei Hirai
Toru Inoue
机构：
[1] Osaka Medical College Hospital,Blood Purification Center
[2] Osaka Rosai Hospital,Department of Laboratory Medicine
[3] Nishimoto Clinic,Department of Nephrology
[4] Arisawa General Hospital,Department of Internal Medicine
[5] Takatsuki General Hospital,undefined
[6] Kanehara Clinic,undefined
[7] Sanko Clinic,undefined
[8] Sanko Fuzoku Clinic,undefined
[9] Okada Clinic,undefined
[10] Kamo Hospital,undefined
[11] Sanko Clinic,undefined
[12] General Hospital Higashikouri,undefined
来源：
Clinical and Experimental Nephrology | 2015年 / 19卷
关键词：
Postmenopausal woman; End-stage renal failure; Raloxifene; Bone metabolism; Vitamin D;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：939 / 946
页数：7
相关论文
共 50 条
  • [41] Raloxifene effects on bone markers, bone mineral density, lipid profile and body composition in postmenopausal women
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S155 - S155
  • [42] Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    Johnell, O
    Scheele, WH
    Lu, YL
    Reginster, JY
    Need, AG
    Seeman, E
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03): : 985 - 992
  • [43] The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women
    Naylor, K. E.
    Clowes, J. A.
    Finigan, J.
    Paggiosi, M. A.
    Peel, N. F. A.
    Eastell, R.
    BONE, 2010, 46 (03) : 592 - 597
  • [44] Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene
    P. J. Meunier
    E. Vignot
    P. Garnero
    E. Confavreux
    E. Paris
    S. Liu-Leage
    S. Sarkar
    T. Liu
    M. Wong
    M. W. Draper
    Osteoporosis International, 1999, 10 : 330 - 336
  • [45] Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene
    Meunier, PJ
    Vignot, E
    Garnero, P
    Confavreux, E
    Paris, E
    Liu-Leage, S
    Sarkar, S
    Liu, T
    Wong, M
    Draper, MW
    OSTEOPOROSIS INTERNATIONAL, 1999, 10 (04) : 330 - 336
  • [46] Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women
    D'Amelio, P
    Muratore, M
    Tinelli, F
    Tamone, C
    Cosention, L
    Quarta, E
    Calcagnile, F
    Isaia, GC
    INTERNATIONAL JOURNAL OF TISSUE REACTIONS-EXPERIMENTAL AND CLINICAL ASPECTS, 2003, 25 (02): : 73 - 78
  • [47] Using in postmenopausal women with bone mass loss raloxifene and alendronate
    Bazarra, A
    Castro, A
    Suarez, M
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S172 - S172
  • [48] Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial
    Ensrud, Kristine E.
    Stock, John L.
    Barrett-Connor, Elizabeth
    Grady, Deborah
    Mosca, Lori
    Khaw, Kay-Tee
    Zhao, Qingwen
    Agnusdei, Donato
    Cauley, Jane A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (01) : 112 - 120
  • [49] The Effects of Raloxifene and Calcium on Lipid Profile in Postmenopausal Women
    Sapmaz, Kadriye
    Coskun, Ayhan
    Guven, Alanur Menekse
    Kiran, Hakan
    Guven, Melih Atahan
    Kiran, Gurkan
    TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 4 (04) : 267 - 271
  • [50] Effects of raloxifene therapy on the anticoagulant system in postmenopausal women
    Azevedo, GD
    Franco, RF
    Baggio, MS
    Maranhao, TMO
    Ferriani, RA
    de Sá, MFS
    CLIMACTERIC, 2003, 6 (02) : 140 - 145
12345